AlphaCore Capital LLC Increases Stock Position in Gilead Sciences, Inc. $GILD

Posted by Brian Himes on May 17th, 2026

Gilead Sciences logo AlphaCore Capital LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 42.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 17,327 shares of the biopharmaceutical company’s stock after acquiring an additional 5,199 shares during the quarter. AlphaCore Capital LLC’s holdings in Gilead Sciences were worth $2,127,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Paulson Wealth Management Inc. grew its holdings in Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares in the last quarter. Alpha Cubed Investments LLC grew its stake in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the period. Personal CFO Solutions LLC grew its stake in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the period. Moss Adams Wealth Advisors LLC grew its stake in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the period. Finally, Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 12.5% in the 4th quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 79 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the insider owned 128,779 shares of the company’s stock, valued at $18,152,687.84. The trade was a 2.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the chief financial officer directly owned 176,191 shares in the company, valued at $24,835,883.36. The trade was a 1.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,000 shares of company stock valued at $9,238,250 in the last 90 days. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 1.9%

GILD stock opened at $129.58 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a market capitalization of $160.88 billion, a price-to-earnings ratio of 17.65 and a beta of 0.31. Gilead Sciences, Inc. has a fifty-two week low of $100.23 and a fifty-two week high of $157.29. The stock has a fifty day moving average of $137.76 and a 200-day moving average of $133.22.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -0.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent analyst reports. Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Cantor Fitzgerald reduced their price objective on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 10th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price objective for the company. Scotiabank upped their price objective on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Finally, Weiss Ratings upgraded Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, May 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $157.04.

Get Our Latest Report on GILD

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.